Get startedLog in
    Picture of Regencell Bioscience Holdings logo

    RGC — Regencell Bioscience Holdings Income Statement

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareHighly SpeculativeLarge CapMomentum Trap
    Balance sheetIncome statementCashflow
    Subscribe to view all data

    Annual income statement for Regencell Bioscience Holdings, fiscal year end - June 30th, USD millions except per share, conversion factor applied.

    2020
    June 30th
    2021
    June 30th
    2022
    June 30th
    2023
    June 30th
    2024
    June 30th
    Period Length:12 M12 M12 M12 M12 M
    Source:PROSPECTUS/A20-F20-F20-F20-F
    Standards:
    USG
    USG
    USG
    USG
    USG
    Status:FinalFinalFinalFinalFinal
    Total Revenue00000
    Selling / General / Administrative Expenses
    Research And Development
    Total Operating Expenses0.8121.387.626.274.74
    Operating Profit-0.812-1.38-7.62-6.27-4.74
    Other Net Non Operating Costs
    Net Income Before Taxes-0.812-1.35-7.59-6.06-4.36
    Provision for Income Taxes
    Net Income After Taxes-0.812-1.35-7.59-6.06-4.36
    Minority Interest
    Net Income Before Extraordinary Items
    Net Income-0.812-1.35-7.45-5.87-4.3
    Income Available to Common Shareholders Excluding Extraordinary Items
    Income Available to Common Shareholders Including Extraordinary Items
    Diluted Net Income-0.812-1.35-7.45-5.87-4.3
    Diluted Weighted Average Shares
    Basic EPS Including Extraordinary Items
    Diluted EPS Including Extraordinary Items
    Diluted EPS Excluding Extraordinary Items
    Normalised Income Before Taxes
    Normalised Income After Taxes
    Normalised Income Available to Common Shareholders
    Diluted Normalised EPS-0.002-0.003-0.015-0.012-0.009
    Dividends per Share